Price
$5.09
Increased by +0.59%
Dollar Volume (20D)
7.41 M
ADR%
5.66
Earnings Report Date (estimate)
May 7, 24
Shares Float
79.52 M
Shares Outstanding
82.11 M
Shares Short
20 M
Market Cap.
415.49 M
Beta
0.58
Price / Earnings
N/A
20D Range
4.48 5.57
50D Range
4.48 6.9
200D Range
4.48 10.45
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Feb 7, 24 -0.11
Increased by +35.29%
-0.14
Increased by +21.43%
Nov 27, 23 -0.12
Increased by +33.33%
-0.15
Increased by +20%
Aug 8, 23 -0.14
Increased by +12.5%
-0.17
Increased by +17.65%
May 9, 23 -0.17
Decreased by -21.43%
-0.19
Increased by +10.53%
Feb 7, 23 -0.17
Decreased by -21.43%
-0.19
Increased by +10.53%
Nov 28, 22 -0.18
Decreased by -20%
-0.16
Decreased by -12.5%
Aug 9, 22 -0.16
Decreased by -14.29%
-0.15
Decreased by -6.67%
May 10, 22 -0.14
Decreased by -16.67%
-0.17
Increased by +17.65%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 23 0
Decreased by N/A%
-8.62 M
Increased by +33.53%
Decreased by N/A%
Decreased by N/A%
Sep 30, 23 0
Decreased by N/A%
-10.15 M
Increased by +29%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0
Decreased by N/A%
-11.28 M
Increased by +8.79%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0
Decreased by N/A%
-13.11 M
Decreased by -25.57%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0
Decreased by N/A%
-12.97 M
Decreased by -19.2%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0
Decreased by N/A%
-14.29 M
Decreased by -21.95%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0
Decreased by N/A%
-12.37 M
Decreased by -21.48%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0
Decreased by N/A%
-10.44 M
Decreased by -27.99%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.